Recombinant Adenoviral Human p53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable, Locally Advanced Head and Neck Cancer - a Open-labeled Randomized Phase 2 Study

Trial Profile

Recombinant Adenoviral Human p53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable, Locally Advanced Head and Neck Cancer - a Open-labeled Randomized Phase 2 Study

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 May 2015

At a glance

  • Drugs Contusugene ladenovec (Primary) ; Cisplatin; Paclitaxel
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors Shenzhen SiBiono GeneTech
  • Most Recent Events

    • 05 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top